

# Activity of fusidic acid (FUS) alone or in combination with daptomycin (DAP), vancomycin (VAN), or linezolid (LDZ) in an *in vitro* model of *Staphylococcus aureus* Biofilm

Wafi Siala,<sup>1</sup> Hector Rodriguez-Villalobos,<sup>2</sup> Prabhavati Fernandes,<sup>3</sup> Paul M. Tulkens,<sup>1</sup> and Françoise Van Bambeke<sup>1</sup>


<sup>1</sup> Pharmacologie cellulaire et moléculaire & Centre de Pharmacie Clinique, Louvain Drug Research Institute. Université Catholique de Louvain, Brussels, Belgium; <sup>2</sup> Laboratoire de microbiologie, Cliniques Universitaires Saint Luc. Université Catholique de Louvain, Brussels, Belgium; <sup>3</sup> Cempra Pharmaceuticals, Chapel Hill, NC, USA

## Introduction


*Staphylococcus aureus* is an important human pathogen causing chronic infections that are difficult to treat. Biofilm contributes to the persistence of infections, by protecting bacteria from immune system and antimicrobial agents. We showed that many antibiotics are poorly active on biofilms [1], especially when using clinical isolates from persistent infections [2]. Fusidic acid (FUS) may constitute a useful alternative for treatment of *Staphylococcus aureus* infections (in regions with low resistance rates) but shows moderate activity against biofilms [1]. Since FUS is commonly used in combination to avoid resistance selection, we examined which other antistaphylococcal antibiotics could at the same time improve, *in vitro*, its activity against mature biofilms of clinical isolates.

## Materials and Methods

*S. aureus* reference strain ATCC25923 and 5 clinical strains isolated on medical devices or from chronic tissue infections were used. Biofilms were grown for 24 h in 96-wells plates and then exposed for 48 h to increasing concentrations (0.25-64 mg/L) of FUS (to obtain full concentration-response curves), combined with concentrations corresponding to the human  $fC_{min}$  or the  $fC_{max}$  of the associated drug. Bacterial viability in biofilms was quantified using the redox indicator resazurin (reduced to fluorescent resorufin by viable bacteria); biofilm biomass was evaluated using crystal violet absorbance.



**Redox indicator resazurin assay:**  
blue-colored wells: dead bacteria ;  
pink-colored wells: viable bacteria  
(blue resazurin reduced in the pink, fluorescent compound resorufin)



**Quantification of matrix**  
by non-specific staining of biofilm constituents with crystal violet


## References

- 1-Bauer, J., Siala, W., Tulkens, P. M. & Van Bambeke, F. (2013) *Antimicrob. Agents Chemother.* **57**, 2726-2737.
- 2-Siala, W., Mingeot-Leclercq, M. P., Tulkens, P. M., Hallin, M., Denis, O. & Van Bambeke, F. (2014) *Antimicrob. Agents Chemother.* **58**, 6385-6397.

## Acknowledgements


WS is a post-doctoral fellow of the program Prospective Research for Brussels from Innoviris). This work was also supported by Cempra Pharmaceuticals.

## Results



Combining FUS at  $fC_{max}$  with daptomycin (DAP), vancomycin (VAN), or linezolid (LZD) improved in general its efficacy, with reduction in viability reaching globally 75-96 % when these companion drugs were used at their  $fC_{max}$

**Fig 1 :** % reduction in viability within biofilms for antibiotics alone or for FUS at  $fC_{max}$  combined with other antibiotics at their respective  $fC_{min}/fC_{max}$ . Reduction in viability was compared to untreated control. FUS  $fC_{max}$ : 35 mg/L; DAP  $fC_{min}/fC_{max}$ : 0.7/9.4 mg/L; VAN  $fC_{min}/fC_{max}$ : 2.5/20 mg/L; LZD  $fC_{min}/fC_{max}$ : 9/17 mg/L



**Fig 2: Concentration-response curves for a typical clinical isolate (80124430375)**  
Viability (% control values) in biofilms exposed to FUS alone over a wide range of conc. (blue);  $fC_{max}$  of DAP, VAN, LZD alone (green) or in combination with FUS at increasing conc. (black)

## Conclusions

Combining FUS with DAP, VAN, or LZD appears as a useful strategy to increase its antibacterial activity against biofilms. These data support the evaluation of these combinations in biofilm-related infections *in vivo*.